Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.

Zhang C, Stockwell SR, Elbanna M, Ketteler R, Freeman J, Al-Lazikani B, Eccles S, De Haven Brandon A, Raynaud F, Hayes A, Clarke PA, Workman P, Mittnacht S.

Oncogene. 2019 Jul;38(30):5905-5920. doi: 10.1038/s41388-019-0850-2. Epub 2019 Jul 12.

PMID:
31296956
2.

Transforming cancer drug discovery with Big Data and AI.

Workman P, Antolin AA, Al-Lazikani B.

Expert Opin Drug Discov. 2019 Jul 8:1-7. doi: 10.1080/17460441.2019.1637414. [Epub ahead of print] No abstract available.

PMID:
31284790
3.

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.

Stewart A, Coker EA, Pölsterl S, Georgiou A, Minchom AR, Carreira S, Cunningham D, O'Brien ME, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U.

Mol Cancer Ther. 2019 Aug;18(8):1396-1404. doi: 10.1158/1535-7163.MCT-18-0727. Epub 2019 Jul 1.

PMID:
31262731
4.

Leveraging Human Genetics to Guide Cancer Drug Development.

Kinnersley B, Sud A, Coker EA, Tym JE, Di Micco P, Al-Lazikani B, Houlston RS.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00077.

5.

canSAR: update to the cancer translational research and drug discovery knowledgebase.

Coker EA, Mitsopoulos C, Tym JE, Komianou A, Kannas C, Di Micco P, Villasclaras Fernandez E, Ozer B, Antolin AA, Workman P, Al-Lazikani B.

Nucleic Acids Res. 2019 Jan 8;47(D1):D917-D922. doi: 10.1093/nar/gky1129.

6.

Genomics, bio specimens, and other biological data: Current status and future directions.

Rosenstein BS, Rao A, Moran JM, Spratt DE, Mendonca MS, Al-Lazikani B, Mayo CS, Speers C.

Med Phys. 2018 Oct;45(10):e829-e833. doi: 10.1002/mp.12912. Epub 2018 Sep 18. Review. No abstract available.

PMID:
30226926
7.

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.

Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.

8.

Objective, Quantitative, Data-Driven Assessment of Chemical Probes.

Antolin AA, Tym JE, Komianou A, Collins I, Workman P, Al-Lazikani B.

Cell Chem Biol. 2018 Feb 15;25(2):194-205.e5. doi: 10.1016/j.chembiol.2017.11.004. Epub 2017 Dec 14.

9.

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.

Cato L, Neeb A, Sharp A, Buzón V, Ficarro SB, Yang L, Muhle-Goll C, Kuznik NC, Riisnaes R, Nava Rodrigues D, Armant O, Gourain V, Adelmant G, Ntim EA, Westerling T, Dolling D, Rescigno P, Figueiredo I, Fauser F, Wu J, Rottenberg JT, Shatkina L, Ester C, Luy B, Puchta H, Troppmair J, Jung N, Bräse S, Strähle U, Marto JA, Nienhaus GU, Al-Lazikani B, Salvatella X, de Bono JS, Cato AC, Brown M.

Elife. 2017 Aug 10;6. pii: e27159. doi: 10.7554/eLife.27159.

10.

SiGNet: A signaling network data simulator to enable signaling network inference.

Coker EA, Mitsopoulos C, Workman P, Al-Lazikani B.

PLoS One. 2017 May 17;12(5):e0177701. doi: 10.1371/journal.pone.0177701. eCollection 2017.

11.

Rational design of non-resistant targeted cancer therapies.

Martínez-Jiménez F, Overington JP, Al-Lazikani B, Marti-Renom MA.

Sci Rep. 2017 Apr 24;7:46632. doi: 10.1038/srep46632.

12.

A comprehensive map of molecular drug targets.

Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP.

Nat Rev Drug Discov. 2017 Jan;16(1):19-34. doi: 10.1038/nrd.2016.230. Epub 2016 Dec 2. Review.

13.

Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Antolin AA, Workman P, Mestres J, Al-Lazikani B.

Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828. Review.

14.

Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.

Al-Lazikani B, Workman P.

Future Med Chem. 2016 Sep;8(14):1711-6. doi: 10.4155/fmc-2016-0133. Epub 2016 Sep 1. No abstract available.

15.

Drug discovery in advanced prostate cancer: translating biology into therapy.

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS.

Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22. Review.

PMID:
27444228
16.

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.

Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ.

Cell Rep. 2016 Mar 15;14(10):2490-501. doi: 10.1016/j.celrep.2016.02.023. Epub 2016 Mar 3.

17.

Blocking the survival of the nastiest by HSP90 inhibition.

Workman P, Clarke PA, Al-Lazikani B.

Oncotarget. 2016 Jan 26;7(4):3658-61. doi: 10.18632/oncotarget.6971.

18.

Distinctive Behaviors of Druggable Proteins in Cellular Networks.

Mitsopoulos C, Schierz AC, Workman P, Al-Lazikani B.

PLoS Comput Biol. 2015 Dec 23;11(12):e1004597. doi: 10.1371/journal.pcbi.1004597. eCollection 2015 Dec.

19.

canSAR: an updated cancer research and drug discovery knowledgebase.

Tym JE, Mitsopoulos C, Coker EA, Razaz P, Schierz AC, Antolin AA, Al-Lazikani B.

Nucleic Acids Res. 2016 Jan 4;44(D1):D938-43. doi: 10.1093/nar/gkv1030. Epub 2015 Dec 15.

20.

Therapeutic opportunities within the DNA damage response.

Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM.

Nat Rev Cancer. 2015 Mar;15(3):166-80. doi: 10.1038/nrc3891. Review.

PMID:
25709118
21.

canSAR: updated cancer research and drug discovery knowledgebase.

Bulusu KC, Tym JE, Coker EA, Schierz AC, Al-Lazikani B.

Nucleic Acids Res. 2014 Jan;42(Database issue):D1040-7. doi: 10.1093/nar/gkt1182. Epub 2013 Dec 3.

22.

Drugging cancer genomes.

Workman P, Al-Lazikani B.

Nat Rev Drug Discov. 2013 Dec;12(12):889-90. doi: 10.1038/nrd4184. No abstract available.

PMID:
24287764
23.

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology.

Workman P, Al-Lazikani B, Clarke PA.

Curr Opin Pharmacol. 2013 Aug;13(4):486-96. doi: 10.1016/j.coph.2013.06.004. Epub 2013 Jun 28. Review.

PMID:
23810823
24.

A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.

Box C, Mendiola M, Gowan S, Box GM, Valenti M, Brandon Ade H, Al-Lazikani B, Rogers SJ, Wilkins A, Harrington KJ, Eccles SA.

Eur J Cancer. 2013 Jul;49(11):2512-21. doi: 10.1016/j.ejca.2013.03.011. Epub 2013 Apr 10.

PMID:
23582742
25.

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J.

Oncogene. 2014 Feb 27;33(9):1148-57. doi: 10.1038/onc.2013.46. Epub 2013 Feb 25.

26.

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P.

Clin Pharmacol Ther. 2013 Mar;93(3):252-9. doi: 10.1038/clpt.2012.237. Epub 2012 Dec 7. Review.

27.

Unpicking the combination lock for mutant BRAF and RAS melanomas.

Al-Lazikani B, Workman P.

Cancer Discov. 2013 Jan;3(1):14-9. doi: 10.1158/2159-8290.CD-12-0520.

28.

Objective assessment of cancer genes for drug discovery.

Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B.

Nat Rev Drug Discov. 2013 Jan;12(1):35-50. doi: 10.1038/nrd3913. Review.

PMID:
23274470
29.

Combinatorial drug therapy for cancer in the post-genomic era.

Al-Lazikani B, Banerji U, Workman P.

Nat Biotechnol. 2012 Jul 10;30(7):679-92. doi: 10.1038/nbt.2284. Review.

PMID:
22781697
30.

Personalized medicine: patient-predictive panel power.

Workman P, Clarke PA, Al-Lazikani B.

Cancer Cell. 2012 Apr 17;21(4):455-8. doi: 10.1016/j.ccr.2012.03.030.

31.

canSAR: an integrated cancer public translational research and drug discovery resource.

Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B.

Nucleic Acids Res. 2012 Jan;40(Database issue):D947-56. doi: 10.1093/nar/gkr881. Epub 2011 Oct 19.

32.

ChEMBL: a large-scale bioactivity database for drug discovery.

Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP.

Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23.

33.

Collation and data-mining of literature bioactivity data for drug discovery.

Bellis LJ, Akhtar R, Al-Lazikani B, Atkinson F, Bento AP, Chambers J, Davies M, Gaulton A, Hersey A, Ikeda K, Krüger FA, Light Y, McGlinchey S, Santos R, Stauch B, Overington JP.

Biochem Soc Trans. 2011 Oct;39(5):1365-70. doi: 10.1042/BST0391365.

PMID:
21936816
34.

Minimum information about a bioactive entity (MIABE).

Orchard S, Al-Lazikani B, Bryant S, Clark D, Calder E, Dix I, Engkvist O, Forster M, Gaulton A, Gilson M, Glen R, Grigorov M, Hammond-Kosack K, Harland L, Hopkins A, Larminie C, Lynch N, Mann RK, Murray-Rust P, Lo Piparo E, Southan C, Steinbeck C, Wishart D, Hermjakob H, Overington J, Thornton J.

Nat Rev Drug Discov. 2011 Aug 31;10(9):661-9. doi: 10.1038/nrd3503. Review.

PMID:
21878981
35.

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV.

Sci Transl Med. 2011 Jun 1;3(85):85ra47. doi: 10.1126/scitranslmed.3002004.

36.

Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation.

Abad-Zapatero C, Perišić O, Wass J, Bento AP, Overington J, Al-Lazikani B, Johnson ME.

Drug Discov Today. 2010 Oct;15(19-20):804-11. doi: 10.1016/j.drudis.2010.08.004. Epub 2010 Aug 19.

PMID:
20727982
37.

The genome of the blood fluke Schistosoma mansoni.

Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, Aslett MA, Bartholomeu DC, Blandin G, Caffrey CR, Coghlan A, Coulson R, Day TA, Delcher A, DeMarco R, Djikeng A, Eyre T, Gamble JA, Ghedin E, Gu Y, Hertz-Fowler C, Hirai H, Hirai Y, Houston R, Ivens A, Johnston DA, Lacerda D, Macedo CD, McVeigh P, Ning Z, Oliveira G, Overington JP, Parkhill J, Pertea M, Pierce RJ, Protasio AV, Quail MA, Rajandream MA, Rogers J, Sajid M, Salzberg SL, Stanke M, Tivey AR, White O, Williams DL, Wortman J, Wu W, Zamanian M, Zerlotini A, Fraser-Liggett CM, Barrell BG, El-Sayed NM.

Nature. 2009 Jul 16;460(7253):352-8. doi: 10.1038/nature08160.

38.

Genomic-scale prioritization of drug targets: the TDR Targets database.

Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AW, Chen F, Crowther GJ, Doyle MA, Hertz-Fowler C, Hopkins AL, McAllister G, Nwaka S, Overington JP, Pain A, Paolini GV, Pieper U, Ralph SA, Riechers A, Roos DS, Sali A, Shanmugam D, Suzuki T, Van Voorhis WC, Verlinde CL.

Nat Rev Drug Discov. 2008 Nov;7(11):900-7. doi: 10.1038/nrd2684. Epub 2008 Oct 17. Review.

39.

Protein structure prediction.

Al-Lazikani B, Hill EE, Morea V.

Methods Mol Biol. 2008;453:33-85. doi: 10.1007/978-1-60327-429-6_2.

PMID:
18712297
40.

How many drug targets are there?

Overington JP, Al-Lazikani B, Hopkins AL.

Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Review.

PMID:
17139284
41.

Defective acute inflammation in Crohn's disease: a clinical investigation.

Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW.

Lancet. 2006 Feb 25;367(9511):668-78. Erratum in: Lancet. 2007 Jul 28;370(9584):318.

PMID:
16503465
42.

Effective function annotation through catalytic residue conservation.

George RA, Spriggs RV, Bartlett GJ, Gutteridge A, MacArthur MW, Porter CT, Al-Lazikani B, Thornton JM, Swindells MB.

Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12299-304. Epub 2005 Jul 21.

43.

The complement of enzymatic sets in different species.

Freilich S, Spriggs RV, George RA, Al-Lazikani B, Swindells M, Thornton JM.

J Mol Biol. 2005 Jun 17;349(4):745-63.

PMID:
15896806
44.

SCOPEC: a database of protein catalytic domains.

George RA, Spriggs RV, Thornton JM, Al-Lazikani B, Swindells MB.

Bioinformatics. 2004 Aug 4;20 Suppl 1:i130-6.

PMID:
15262791
45.

Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains.

Sheinerman FB, Al-Lazikani B, Honig B.

J Mol Biol. 2003 Dec 5;334(4):823-41.

PMID:
14636606
46.
47.

Protein structure prediction.

Al-Lazikani B, Jung J, Xiang Z, Honig B.

Curr Opin Chem Biol. 2001 Feb;5(1):51-6. Review.

PMID:
11166648
48.

Canonical structures for the hypervariable regions of T cell alphabeta receptors.

Al-Lazikani B, Lesk AM, Chothia C.

J Mol Biol. 2000 Jan 28;295(4):979-95.

PMID:
10656805
49.

Standard conformations for the canonical structures of immunoglobulins.

Al-Lazikani B, Lesk AM, Chothia C.

J Mol Biol. 1997 Nov 7;273(4):927-48.

PMID:
9367782

Supplemental Content

Loading ...
Support Center